Find out what our scientists are working on to improve diagnosis, therapy and treatment of lung diseases step by step.
How can chronic lung diseases in babies be diagnosed earlier and better? DZL researchers in Munich and Giessen are on the trail of three promising proteins.
In einer Pilotstudie messen IPF-Patienten zuhause ihre Lungenvitalkapazität. Die Messwerte könnten einen Hinweis auf akute Krankheitsverschlechterungen liefern.
Mit Hilfe von Stammzellen kann sich Lungengewebe regenerieren. Das könnte Abstoßungsreaktionen bei Lungentransplantationen verhindern.
The combination of single-cell analysis and artificial intelligence provides a unique insight into the complex aging of lung cells
The imaging platform of radiology at Munich University Hospital is breaking new ground in the diagnosis of lung diseases with new techniques and equipment.
The poor course of the chronic obstructive pulmonary disease could be slowed down with an agent from the azole group. But what is the best way for this agent to reach its target, the lungs?
A working group at the Walther Straub Institute for Pharmacology and Toxicology at LMU Munich is investigating TRP proteins as target structures for new drugs.
The immunoproteasome is responsible for quality control in the cell and could therefore be a starting point for a new biomarker to predict the worsening of COPD.
Fibrotic lung diseases usually progress quickly. Researchers of the CPC-M are investigating a protein which could stop the collagen formation in the lung tissue – and thus the scarring.
In the ALLIANCE study, DZL scientists and physicians try to close gaps in knowledge regarding the pathogenesis and progression of asthma in children.
A research group at the CPC-M is investigating the development of these OP-related adhesions – and how they can be treated better than before.
Interstitial lung diseases in children are an enigma in lung medicine. The Germany-wide chILD-EU study aims to close this gap and systematically search for new therapies.
At the Asklepios Clinic in Gauting, the biobank team collects samples from patients with lung diseases – indispensable substances for science.
For the first time, scientists in Bavaria are comprehensively analyzing how COPD patients are treated – and how this affects the progression of the disease as well as the lives of patients.